Regeneron Depreciation vs Change To Inventory Analysis

REGN Stock

USD 716.90 20.02 2.87%

Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Depreciation and its Change To Inventory accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Depreciation vs Change To Inventory

Depreciation vs Change To Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Depreciation account and Change To Inventory. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Regeneron Pharmaceuticals' Depreciation and Change To Inventory is -0.56. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Change To Inventory in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Depreciation and Change To Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Regeneron Pharmaceuticals are associated (or correlated) with its Change To Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Inventory has no effect on the direction of Depreciation i.e., Regeneron Pharmaceuticals' Depreciation and Change To Inventory go up and down completely randomly.

Correlation Coefficient

-0.56

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Depreciation

Depreciation indicates how much of Regeneron Pharmaceuticals value has been used up. For tax purposes Regeneron Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Regeneron Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 13th of January 2025, Tax Provision is likely to grow to about 584.1 M, while Issuance Of Capital Stock is likely to drop about 1.3 B.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	5.6B	7.1B	8.1B	8.5B
Cost Of Revenue	1.6B	883.7M	1.0B	1.1B

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Accounts Payable	Short Term Debt	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab
Total Assets		0.98	1.0	0.96	0.0	0.99	0.97	0.95	-0.15	0.96	0.98	0.21	0.96	0.32	-0.73	0.98	0.98	0.88	0.89	0.96	0.98	0.58	0.99	0.95	0.99	0.57
Total Current Liabilities	0.98		0.96	0.95	0.02	0.96	0.99	0.87	-0.23	0.98	0.99	0.24	0.96	0.44	-0.72	0.99	0.99	0.8	0.93	0.91	0.99	0.68	0.97	0.87	0.98	0.56
Total Stockholder Equity	1.0	0.96		0.95	-0.01	1.0	0.96	0.96	-0.16	0.96	0.97	0.19	0.95	0.29	-0.73	0.97	0.97	0.9	0.86	0.96	0.97	0.55	0.99	0.96	0.98	0.55
Property Plant And Equipment Net	0.96	0.95	0.95		-0.09	0.92	0.94	0.9	-0.09	0.92	0.96	0.34	0.97	0.39	-0.55	0.97	0.95	0.76	0.87	0.87	0.96	0.67	0.97	0.86	0.97	0.75
Net Debt	0.0	0.02	-0.01	-0.09		0.06	-0.04	0.06	0.14	-0.08	0.04	-0.13	0.12	0.05	-0.49	0.07	-0.03	0.09	0.3	-0.08	-0.02	-0.07	-0.03	0.07	0.0	-0.38
Retained Earnings	0.99	0.96	1.0	0.92	0.06		0.95	0.95	-0.17	0.95	0.97	0.14	0.94	0.28	-0.8	0.96	0.97	0.91	0.88	0.96	0.96	0.53	0.98	0.96	0.97	0.48
Cash	0.97	0.99	0.96	0.94	-0.04	0.95		0.85	-0.23	0.99	0.98	0.27	0.94	0.45	-0.69	0.98	0.99	0.78	0.92	0.91	0.98	0.68	0.96	0.86	0.98	0.55
Non Current Assets Total	0.95	0.87	0.96	0.9	0.06	0.95	0.85		0.0	0.83	0.89	0.16	0.91	0.19	-0.7	0.9	0.87	0.93	0.78	0.9	0.89	0.42	0.95	0.99	0.92	0.56
Non Currrent Assets Other	-0.15	-0.23	-0.16	-0.09	0.14	-0.17	-0.23	0.0		-0.31	-0.13	-0.02	0.0	0.05	0.2	-0.12	-0.24	-0.27	-0.15	-0.17	-0.15	0.06	-0.14	-0.06	-0.15	0.0
Cash And Short Term Investments	0.96	0.98	0.96	0.92	-0.08	0.95	0.99	0.83	-0.31		0.97	0.23	0.91	0.39	-0.7	0.96	0.99	0.78	0.88	0.93	0.97	0.65	0.95	0.84	0.96	0.52
Net Receivables	0.98	0.99	0.97	0.96	0.04	0.97	0.98	0.89	-0.13	0.97		0.26	0.97	0.38	-0.72	0.99	0.99	0.79	0.93	0.93	0.98	0.66	0.98	0.88	0.98	0.56
Common Stock Shares Outstanding	0.21	0.24	0.19	0.34	-0.13	0.14	0.27	0.16	-0.02	0.23	0.26		0.31	0.21	0.24	0.28	0.23	0.05	0.25	0.13	0.25	0.27	0.25	0.09	0.21	0.49
Non Current Liabilities Total	0.96	0.96	0.95	0.97	0.12	0.94	0.94	0.91	0.0	0.91	0.97	0.31		0.44	-0.67	0.99	0.94	0.77	0.94	0.86	0.97	0.68	0.96	0.88	0.97	0.63
Other Current Assets	0.32	0.44	0.29	0.39	0.05	0.28	0.45	0.19	0.05	0.39	0.38	0.21	0.44		-0.17	0.44	0.39	0.05	0.51	0.18	0.47	0.77	0.3	0.16	0.43	0.25
Other Stockholder Equity	-0.73	-0.72	-0.73	-0.55	-0.49	-0.8	-0.69	-0.7	0.2	-0.7	-0.72	0.24	-0.67	-0.17		-0.7	-0.71	-0.76	-0.75	-0.73	-0.69	-0.29	-0.68	-0.76	-0.7	0.05
Total Liab	0.98	0.99	0.97	0.97	0.07	0.96	0.98	0.9	-0.12	0.96	0.99	0.28	0.99	0.44	-0.7		0.98	0.79	0.95	0.9	0.99	0.69	0.98	0.88	0.99	0.6
Total Current Assets	0.98	0.99	0.97	0.95	-0.03	0.97	0.99	0.87	-0.24	0.99	0.99	0.23	0.94	0.39	-0.71	0.98		0.81	0.9	0.94	0.99	0.65	0.97	0.88	0.98	0.54
Intangible Assets	0.88	0.8	0.9	0.76	0.09	0.91	0.78	0.93	-0.27	0.78	0.79	0.05	0.77	0.05	-0.76	0.79	0.81		0.7	0.87	0.79	0.22	0.86	0.96	0.83	0.38
Short Long Term Debt Total	0.89	0.93	0.86	0.87	0.3	0.88	0.92	0.78	-0.15	0.88	0.93	0.25	0.94	0.51	-0.75	0.95	0.9	0.7		0.75	0.92	0.69	0.87	0.77	0.91	0.45
Other Current Liab	0.96	0.91	0.96	0.87	-0.08	0.96	0.91	0.9	-0.17	0.93	0.93	0.13	0.86	0.18	-0.73	0.9	0.94	0.87	0.75		0.91	0.44	0.95	0.93	0.91	0.46
Accounts Payable	0.98	0.99	0.97	0.96	-0.02	0.96	0.98	0.89	-0.15	0.97	0.98	0.25	0.97	0.47	-0.69	0.99	0.99	0.79	0.92	0.91		0.73	0.97	0.88	0.99	0.59
Short Term Debt	0.58	0.68	0.55	0.67	-0.07	0.53	0.68	0.42	0.06	0.65	0.66	0.27	0.68	0.77	-0.29	0.69	0.65	0.22	0.69	0.44	0.73		0.58	0.37	0.65	0.46
Property Plant And Equipment Gross	0.99	0.97	0.99	0.97	-0.03	0.98	0.96	0.95	-0.14	0.95	0.98	0.25	0.96	0.3	-0.68	0.98	0.97	0.86	0.87	0.95	0.97	0.58		0.94	0.98	0.63
Short Term Investments	0.95	0.87	0.96	0.86	0.07	0.96	0.86	0.99	-0.06	0.84	0.88	0.09	0.88	0.16	-0.76	0.88	0.88	0.96	0.77	0.93	0.88	0.37	0.94		0.91	0.46
Inventory	0.99	0.98	0.98	0.97	0.0	0.97	0.98	0.92	-0.15	0.96	0.98	0.21	0.97	0.43	-0.7	0.99	0.98	0.83	0.91	0.91	0.99	0.65	0.98	0.91		0.59
Other Liab	0.57	0.56	0.55	0.75	-0.38	0.48	0.55	0.56	0.0	0.52	0.56	0.49	0.63	0.25	0.05	0.6	0.54	0.38	0.45	0.46	0.59	0.46	0.63	0.46	0.59

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	17.2B	25.4B	29.2B	33.1B	38.0B	39.9B
Total Current Liabilities	2.8B	3.5B	3.8B	3.4B	3.9B	4.1B
Total Stockholder Equity	11.0B	18.8B	22.7B	26.0B	29.9B	31.4B
Property Plant And Equipment Net	3.2B	3.5B	3.8B	4.1B	4.8B	5.0B
Net Debt	502M	(185.9M)	(404.5M)	(27.1M)	(24.4M)	(25.6M)
Retained Earnings	10.9B	19.0B	23.3B	27.3B	31.3B	32.9B
Cash	2.2B	2.9B	3.1B	2.7B	3.1B	3.3B
Non Current Assets Total	4.4B	4.9B	7.1B	13.6B	15.6B	16.4B
Non Currrent Assets Other	328.9M	555.2M	(4.7B)	444.1M	399.7M	419.7M
Cash And Short Term Investments	6.7B	12.5B	14.3B	10.8B	12.5B	13.1B
Net Receivables	4.1B	6.0B	5.3B	5.7B	6.5B	6.8B
Common Stock Shares Outstanding	115.1M	112.2M	113.5M	113.7M	130.8M	75.4M
Liabilities And Stockholders Equity	17.2B	25.4B	29.2B	33.1B	38.0B	39.9B
Non Current Liabilities Total	3.3B	3.2B	2.7B	3.7B	4.2B	4.4B
Other Current Assets	1.2B	664.8M	411.2M	386.6M	444.6M	466.8M
Other Stockholder Equity	102.9M	(173.4M)	(404M)	(1.2B)	(1.4B)	(1.3B)
Total Liab	6.1B	6.7B	6.6B	7.1B	8.2B	8.6B
Total Current Assets	12.8B	20.5B	22.1B	19.5B	22.4B	23.5B
Short Long Term Debt Total	3.6B	2.7B	2.7B	2.7B	3.1B	3.3B
Other Current Liab	122.4M	2.2B	2.1B	2.4B	2.7B	2.8B
Accounts Payable	475.5M	564M	589.2M	606.6M	697.6M	732.5M
Property Plant And Equipment Gross	3.2B	4.9B	5.4B	6.1B	7.0B	7.4B
Accumulated Other Comprehensive Income	29.3M	(26.2M)	(238.8M)	(80.9M)	(72.8M)	(69.2M)
Short Term Investments	1.4B	2.8B	4.6B	8.1B	9.3B	9.8B
Inventory	1.9B	2.0B	2.4B	2.6B	3.0B	3.1B
Other Liab	889M	635.5M	515.3M	707.8M	814.0M	854.7M
Other Assets	2.8B	555.2M	747.6M	(1.0)	(1.15)	(1.09)
Property Plant Equipment	2.9B	3.2B	3.5B	3.8B	4.3B	4.5B
Current Deferred Revenue	577.7M	442M	547.7M	458.9M	527.7M	554.1M
Net Tangible Assets	11.1B	11.0B	18.8B	21.7B	25.0B	26.3B
Retained Earnings Total Equity	7.4B	10.9B	19.0B	23.3B	26.8B	28.1B
Long Term Debt Total	713.9M	2.0B	2.0B	2.0B	2.3B	2.4B
Capital Surpluse	4.4B	6.7B	8.1B	9.9B	11.4B	12.0B

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Regeneron Stock

0.65	DNLI	Denali Therapeutics	Pair Corr
0.68	FOLD	Amicus Therapeutics	Pair Corr
0.87	JNJ	Johnson Johnson Earnings Call Next Week	Pair Corr

Moving against Regeneron Stock

0.9	LFCR	Lifecore Biomedical	Pair Corr
0.82	BMY	Bristol Myers Squibb	Pair Corr
0.74	GILD	Gilead Sciences	Pair Corr
0.43	IMCC	Im Cannabis Corp	Pair Corr
0.39	INCY	Incyte	Pair Corr

The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.

The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.298

Earnings Share

40.42

Revenue Per Share

128.691

Quarterly Revenue Growth

0.106

Return On Assets

0.0741

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Depreciation vs Change To Inventory Analysis

Depreciation vs Change To Inventory

Depreciation vs Change To Inventory Correlation Analysis

Correlation Coefficient

Depreciation

Change To Inventory

Regeneron Pharmaceuticals fundamental ratios Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals fundamental ratios Accounts

Pair Trading with Regeneron Pharmaceuticals

Moving together with Regeneron Stock

Moving against Regeneron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Stockholder Equity
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Inventory	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities

Other Stockholder Equity	- 0.8	Retained Earnings
Short Term Investments	- 0.76	Other Stockholder Equity
Intangible Assets	- 0.76	Other Stockholder Equity
Short Long Term Debt Total	- 0.75	Other Stockholder Equity
Other Current Liab	- 0.73	Other Stockholder Equity
Other Stockholder Equity	- 0.73	Total Stockholder Equity